Cellectis bioresearch launches cGPS® CHO-S CEMAX®

InfoWeb Marketplace

Cellectis bioresearch launches cGPS® CHO-S CEMAX®
Monday, November 2, 2009Description :
Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis S.A. (Alternext: ALCLS), today marketed cGPS® CHO-S CEMAX®, which enables targeted integration into suspended cells. By reducing the time required to obtain the clones and by making it possible to obtain a very good stability of production over time, this kit represents a real step forward in the production of recombinant proteins and monoclonal antibodies. The production of antibodies for research and diagnosis will be facilitated.

The culture of cells in suspension makes it possible to obtain a volume and a cell concentration well above the culture of adherent cells. By allowing targeted integration in CHO cells cultured in suspension in a selected site allowing a strong expression of proteins, cGPS CHO-S CEMAX opens up a whole new field of applications.

"To develop cGPS CHO-S CEMAX, we used Celonic's CEMAX® technology, which we obtained a license just over 5 months ago," said Luc Selig, Sales and Marketing Director of Cellectis bioresearch. "By optimizing CEMAX®, based on our technologies, for the fields of use of our kits, we offer laboratories a truly powerful tool. "

"Our teams have proven to be able to enrich our product portfolio very quickly through in-licensing," added Marc Le Bozec, CEO of Cellectis bioresearch. "This new product delivers unmatched performance levels to date. "

The targeted integration kits - cGPS® (cellular Genome Positioning System) and cGPS® Custom - are available for sale at www.cellectis-bioresearch.com.

About Cellectis bioresearch

Cellectis bioresearch, a commercial subsidiary of Cellectis SA (Alternext: ALCLS) created in June 2008, offers life science researchers genome customization kits that enable rapid and easy integration of a gene into a precise position of the genome. A given cell type.

About Cellectis S.A.

Cellectis SA is a world leader in genome engineering and genome surgery. The company specializes in the development and production of meganucleases dedicated to in vivo genome surgery, which are used in the therapeutic, agri-food, bioproduction and research fields. The company has signed more than 50 industrial agreements globally with pharmaceutical laboratories, agrochemicals and biotechnology companies, as well as more than 20 partnerships with academic teams. Since its inception, the company has raised more than ? 50 million in private and public financing and is listed on the Alternext market of NYSE Euronext (code: ALCLS).

Cautionary Note

This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, Cellectis shares in any country. This press release contains forward-looking statements about the Company's objectives. These forward-looking statements are based on current estimates and expectations of the Company's management and are subject to risks and uncertainties such as the Company's ability to implement its strategy, the pace of development of the relevant market, Technological and competitive environment, and all risks related to managing the growth of the Company. The Company's objectives set forth in this release may not be achieved as a result of these or other factors of risk and uncertainty as described in, among other things, the prospectus prepared by the Company on its An IPO and received from the Autorité des marchés financiers (AMF) the visa n ° 07023 dated 22 January 2007.

Grouped quotes (0)